


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07H 19/10, A61K 31/70</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/62921</p> <p>(43) International Publication Date: 9 December 1999 (09.12.99)</p>
<p>(21) International Application Number: PCT/CA99/00465</p> <p>(22) International Filing Date: 1 June 1999 (01.06.99)</p> <p>(30) Priority Data: 60/087,569 1 June 1998 (01.06.98) US</p> <p>(71) Applicant (for all designated States except US): S & T SCIENCE AND TECHNOLOGY INC. [-/-]; P.O. Box 3443, Tropic Isle Building, Road Town, Tortola (VG).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): ALEXANDROVNA, Alexandrova Lioudmila [RU/RU]; ul. Fersmana, 3-70, Moscow, B-312 117312 (RU). ANTONOVICH, Krayevsky Alexander [RU/RU]; Profsouznaya al. 132-4-11, Moscow, 117321 (RU). ADANI, Alexander [CA/CA]; 126 Pine Valley Crescent, Woodbridge, Ontario L4L 2W4 (CA).</p> <p>(74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: ANTIVIRAL PHOSPHORUS DERIVATIVES OF 4'-THIO-5-ETHYL-2'-DEOXYURIDINE



(57) Abstract

4'-Thio-5-ethyl-2'-deoxyuridine 5'-phosphonate of formula (II) wherein R=H, CONH₂, AlkylOOC, Alkyl, Haloidalkyl, dihaloidalkyls, trihaloidalkyl, HOCH₂, AcylOCH₂.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						


ANTIVIRAL PHOSPHORUS DERIVATIVES OF 4'-THIO-5-ETHYL-2'-DEOXYURIDINE

FIELD OF THE INVENTION

The present invention relates to novel inhibitors and, more specifically, to novel 4'-thio-5-ethyl-2'-deoxyuridine 5'-phosphonates, which inhibit the reproduction of the human Herpes viruses (HSV-1, HSV-2, TK⁻ HSV-1), Human Cytomegalovirus (HCMV) and Vaccinia virus (VV) in cell cultures.

BACKGROUND OF THE INVENTION


Known in the art are various compounds inhibiting the reproduction of the human Herpes viruses (HSV). The compounds known as TEDU (4'-thio-5-ethyl-2'-deoxyuridine) (Formula I) and as shown below, inhibits HSV (HSV-1, HSV-2) reproduction in cell cultures but it has two negative properties. First, TEDU has generally unacceptable toxicity in human and cell free systems with DNA polymerases. Second, TEDU does not inhibit thymidine kinase defective (TK⁻ HSV-1) herpes viruses [1-3].




(I)

SUMMARY OF THE INVENTION

The present invention is directed to novel compounds exhibiting a selective inhibition of the reproduction of the HSV-1, HSV-2, TK⁻ HSV, HCMV and VV and which possess low toxicity. The present compounds are II and III of the formula as follows:



(II)



(III)


wherein for Formula II, R=H, CONH₂, AlkylOOC, Alkyl, Haloidalkyl, dihaloidalkyls, trihaloidalkyls, HOCH₂, AcylOCH₂, and wherein for Formula III, R= is as defined in Formula II and R'=O-alkyl, O-aminoalkyls, O-hydroxyalkyls, O-glycosyl

These compounds of Formula II and III are capable of inhibiting the reproduction of HSV and are less toxic as compared to the prior art compounds.

DETAILED DESCRIPTION OF THE INVENTION

Synthesis of compounds II and III can be made according to Scheme 1 (one arrow essentially corresponds to one chemical step).

Scheme 1



Another synthetic pathway which may be used does not involve the preliminary protection of 3'-hydroxyl as set out in Scheme 2 below (here also one arrow essentially corresponds to one chemical step). According to Scheme 2, synthesis of compounds of Formula II and III are developed with essentially one chemical step starting from the compound of Formula I. Selection between Schemes 1 and 2 generally depends on the yield of the desired compound. In some cases, the yield is higher when the desired compound is synthesized according to Scheme 1, but in other cases Scheme 2 produces higher yields. Yields of II and III ranged from 20-70% with schemes 1 and 2.

Scheme 2



The compounds according to the present invention are white amorphous powders, readily soluble in water, with low solubility in ethanol and dimethylsulfoxide. They have been found generally to be insoluble in other organic solvents.


The purity and structure of the compounds according to the present invention were proven by chromatography, UV, mass- and NMR-spectroscopy.

EXAMPLE 1

3'-O-Acetyl-I was synthesized according to [3].

Synthesis of 4'-thio-5-ethyl-2'-deoxyuridine 5'-hydrogenphosphonate (II, R=H)

(Scheme 1).



To a solution of phosphite acid (51 mg, 0.8 mmol) in water (2 ml), pyridine (3ml) and tri-*n*-butylamine (148 mg, 0.8 mmol) was added. The solution was evaporated, coevaporated with pyridine (3x5 ml) and then with dimethylformamide (3x5 ml). The residue was dissolved in pyridine (5 ml), 4'-thio-5-ethyl-2'-deoxy-3'-O-acetyluridine (IV, 180 mg, 0.57 mmol) and N,N'-dicyclohexylcarbodiimide (800 mg, 3.8 mmol) were added. The reaction was mixed at +20°C for 20 h, then ice-cold water (5 ml) was added. After mixing during 1 h at +4°C the reaction was diluted with water (150 ml) and applied onto a DEAE-Toyopearl column (2.5 x 12 cm. HCO₃⁻ form), elution was made with a linear gradient of NH₄HCO₃ (0 -> 0.15M, 1 l). The fractions containing the product


were evaporated and coevaporated with water (3 x 10 ml). The residue was dissolved in 25% NH_4OH and kept at $+4^\circ\text{C}$ for 20 h. then evaporated. coevaporated with water (2x5ml). Then it was purified on a LiChroprep RP-18 column (2 x 15 cm), elution was made with 0.01M NH_4HCO_3 to yield 120 mg (63%).

UV (water) λ_{max} 272nm (ϵ 9800). $^1\text{H-NMR}$ (D_2O), ppm, J Hz: 7.77s (1H, H-6), 6.69 d (1H, J_{HP} 632, H-P), 6.25dd (1H, J 2, J 7.5, H-1'), 4.52m (1H, H-3'), 3.86-4.05m, (2H, 5'a, 5'b), 3.55m (1H, H-4'), 2.17-2.40 m (4H, 2'a, 2'b, $\text{CH}_2(\text{Ura})$), 1.0 t (3H, J 7.5, $\text{CH}_3\text{CH}_2(\text{Ura})$). $^{31}\text{P-NMR}$ (D_2O) δ 7.2s. Mass: m/z : 336 [M^+-1].

EXAMPLE 2

Synthesis of 4'-thio-5-ethyl-2'-deoxyuridine 5'-ethoxycarbonylphosphonate (II, $\text{R}=\text{COOEt}$)

(Scheme 2)



To a solution of morpholinium ethoxycarbonylphosphonate (59.3 mg, 0.24 mmol) in water Dowex 50W (Py^+ , 0.5 ml) was added. The precipitate was filtered, washed with water (10 ml), pyridine (5 ml) and tri-*n*-butylamine (44 mg, 0.24 mmol) was added, the resulting solution was evaporated, coevaporated with pyridine (3x5 ml), dissolved in pyridine and 4'-thio-5-ethyl-2'-deoxyuridine I (54 mg, 0.2 mmol) in was added. The solution was evaporated with pyridine (3x5 ml) and dimethylformamide (3x5 ml). The residue was dissolved in dimethylformamide (5 ml) and then


N,N'-dicyclohexylcarbodiimide (124 mg, 0.6 mmol) was added, the reaction mixture was kept at +20°C for 20 h, then cold water (5 ml) was added. After mixing for 1 h at +4°C the mixture was diluted with water (150 ml) and applied onto a DEAE-Toyopearl column (2.5 x 12 cm, HCO₃⁻-form), elution was made with a linear gradient of NH₄HCO₃ (0 → 0.15M, 1 l). The fractions containing the product were evaporated and coevaporated with water (3 x 10 ml). The residue was purified on a LiChroprep RP-8 column (2 x 15 cm), elution being made with a linear gradient of MeOH (0 → 10%, 1 l) in 0.01M NH₄HCO₃ to yield 35 mg (43%).

UV (water) λ_{\max} 272nm (ϵ 9800), ¹H-NMR (D₂O), δ , ppm, *J* Hz: 7.77s (1H, H-6), 6.25dd (1H, *J* 2, *J* 7.5, H-1'), 4.65m (1H, H-3'), 3.9-4.1m (3H, CH₃CH₂O, 5'a, 5'b), 3.55m (1H, H-4'), 2.37-2.40 m (1H, 2'a), 2.21-2.28 m (3H, 2'b, CH₂(Ura)), 1.18 dt (3H, *J*_{CH₃P} 1.1, *J*_{CH₃CH₂} 7, CH₃CH₂O), 0.98t (3H, *J* 7.5, CH₃CH₂ (Ura)). ³¹P-NMR (D₂O) δ -3.9s. Mass: *m/z*: 408 [M⁺].

EXAMPLE 3

Synthesis of 4'-thio-5-ethyl-2'-deoxyuridine 5'-hydrogenphosphonate (II, R=H)

(Scheme 2)




To a solution of phosphite acid (51 mg, 0.8 mmol) in water (2 ml) pyridine (3 ml) and tri-*n*-butylamine (148 mg, 0.8 mmol) was added. The solution was evaporated, coevaporated with pyridine (3x5 ml) and then with dimethylformamide (3x5 ml). The residue was dissolved in pyridine (5 ml), 4'-

thio-5-ethyl-2'-deoxyuridine (I, 165 mg, 0.57 mmol) and *N,N'*-dicyclohexylcarbodiimide (800 mg, 3.8 mmol) were added. The reaction was mixed at +20°C for 20 h, then ice-cold water (5 ml) was added. After mixing during 1 h at +4°C the reaction was diluted with water (150 ml) and applied onto a DEAE-Toyopearl column (2.5 x 12 cm, HCO₃⁻ form), elution was made with a linear gradient of NH₄HCO₃ (0 - > 0.15M, 1 l). The fractions containing the product were evaporated and coevaporated with water (3 x 10 ml). The residue was purified on a LiChroprep RP-18 column (2 x 15 cm), elution was made with 0.01M NH₄HCO₃ to yield 90 mg (47%).

UV (water) λ_{\max} 272nm (ϵ 9800). ¹H-NMR (D₂O), ppm, *J* Hz: 7.77s (1H, H-6), 6.69 d (1H, *J*_{H-P} 632, H-P), 6.25dd (1H, *J* 2, *J* 7.5, H-1'), 4.52m (1H, H-3'), 3.86-4.05m, (2H, 5'a, 5'b), 3.55m (1H, H-4'), 2.17-2.40 m (4H, 2'a, 2'b, CH₂(Ura)), 1.0 t (3H, *J* 7.5, CH₃CH₂ (Ura)). ³¹P-NMR (D₂O) δ 7.2s. Mass: *m/z*: 336 [*M*⁺+1].

EXAMPLE 4

Synthesis of 4'-thio-5-ethyl-2'-deoxyuridine 5'-(trimethylcarbonyloxymethylene-hydrogenphosphonate) (III, R=H)




To a solution of trimethylcarbonyloxymethylene hydrogenphosphonate (84 mg, 0.5 mmol) in pyridine (5 ml) tri-*n*-butylamine (93 mg, 0.5 mmol) was added. the resulting solution was evaporated.

coevaporated with pyridine (3x5 ml), dissolved in pyridine and 4'-thio-5-ethyl-2'-deoxyuridine I (108 mg, 0.4 mmol) in was added. The solution was evaporated with pyridine (3x5 ml) and dimethylformamide (3x5 ml). The residue was dissolved in dimethylformamide (5 ml) and then *N,N'*-dicyclohexylcarbodiimide (248 mg, 1.2 mmol) was added, the reaction mixture was kept at +20°C for 20 h, then cold water (5 ml) was added. After mixing for 1 h at +4°C the mixture was diluted with water (150 ml) and applied onto a DEAE-Toyopearl column (2.5 x 12 cm, HCO₃⁻-form), elution was made with a linear gradient of NH₄HCO₃ (0 → 0.15M, 1 l). The fractions containing the product were evaporated and coevaporated with water (3 x 10 ml). The residue was purified on a LiChroprep RP-8 column (2 x 15 cm), elution being made with a linear gradient of MeOH (0 → 10%, 1 l) in 0.01M NH₄HCO₃ to yield 82.5 mg (49%).

UV (water) λ_{max} 272nm (ϵ 9800), ¹H-NMR (D₂O), δ , ppm, *J* Hz: 7.77s (1H, H-6), 6.69 d (1H, *J*_{HP} 632, H-P), 6.22dd (1H, *J* 2, *J* 7.5, H-1'), 5.63d (2H, *J* 14, OCH₂O), 4.55m (1H, H-3'), 3.8-4.1m (2H, H-5'a, 5'b), 3.52m (1H, H-4'), 2.37-2.40 m (1H, H-2'a), 2.21-2.28 m (3H, 2'b, CH₂(Ura)), 1.18 s (9H, C(CH₃)), 0.99t (3H, *J* 7.5, CH₂CH₂ (Ura)). Mass: *m/z*: 421 [M⁺].

EXAMPLE 5

Viral Plaque Reduction Assays.




Antiviral assays of II. R=C₂H₅OOC were performed using an adaptation of the plaque reduction assay described in [4]. Twenty-four well plates containing monolayers of MCR 5 cells (human embryo lung fibroblasts, ATCC CCL 171) were used for assay of varicella zoster virus (VZV strain G31), and

monolayers of Vero cells (African Green monkey kidney, ATCC CCLB1) were used for herpes simplex virus type 1 (HSV-1) strain SC16 and HSV-2 (strain 186). Monolayers were infected with virus at a multiplicity calculated to produce 60-80 plaques per well. Infected cells were overlaid with liquid growth medium containing various known concentrations of the compound under investigation, and, in the case HSV-1 and HSV-2, carboxymethyl cellulose to prevent the formation of secondary plaques. Following a suitable period of incubation, plaques were fixed with formol saline and stained, and their numbers were determined. For IC_{50} determination, a dose-response curve was obtained and from this the 50% inhibitory concentration (IC_{50}) was obtained. Tables 1 (first testing) and 2 (second independent testing) demonstrate these data for different viruses. The well known antiviral drugs are shown as controls: BVDU - 5-bromovinyl-2'-deoxyuridine; ribovirin; ACG - acyclovir; DHPG - gancyclovir.

EXAMPLE 6

Cytotoxicity assay of II, $R=C_2H_5OOC$



Subconfluent cultures of Vero or MRC-5 cells were grown in 96-well microtiter plates in the presence of different dilutions of drug. Cell numbers present at 96h (Vero) and 7 days (MRC-5) were estimated, on replicate cultures, using uptake of a tetrazolium dye (MTT). The concentration required for a 50% inhibition of cell growth compared to control cell growth in the absence of compound is termed $CCID_{50}$. Cytotoxicity assays were performed using Vero cells and MRC-5 cells.

For 50% cytotoxic concentration (CC_{50}) determination, a dose-response curve was obtained. Tables 1 (first testing) and 2 (second independent testing) demonstrate these data for cells. The well known antiviral drugs are shown as controls: BVDU - 5-bromovinyl-2'-deoxyuridine; ribovirin; ACG - acyclovir, DHPG - gancyclovir.

The compounds according to the present invention, viz 4'-thio-5-ethyl-2'-deoxyuridine 5'-phosphonates have shown to be capable of selective inhibition of the reproduction of the HSV-1 and HSV-2 viruses in cell cultures. It is expected that this same selective inhibition of the reproduction of TK⁻ HSV-1, HSMV and VV viruses will be exhibited by the compounds of Formula II and III. It is expected that the compounds of Formula II and III will be effective in the treatment of these viruses, including prophylactic treatment.

Table I. Antiviral activity and cytotoxicity of TEDU (I) and its phosphonate (II, R=COOEt) in E₆SM cell cultures.

Compound	Minimum cytotoxic concentration, mM	Minimum inhibitory concentration, mM									
		HSV-1 (KOS)	HSV-1 (F)	HSV-1 (Mclaryre)	HSV-2 (O)	HSV-2 (196)	HSV-2 (Lyon)	Vaccinia virus	Vesicular stomatitis virus	HSV-1 TK ^a (B2008)	HSV-1 TK ^a (VMW 1837)
I (I)	>500	0.17-0.5 >(1000-2950) ^c			2-5 >(100-250)			0.99 >505			
II, R=COOEt	>950	0.036 >26400	0.036 >26400	0.036 >26400	0.17 >5590	0.17 >5590	0.17 >5590	0.17 >5590	1.45 >660	0.17 >5590	0.17 >5590
HSVDI	>240	0.046 >5220	0.046 >5220	0.046 >5220	>240	>240	>240	5.76 >42	>1200	48 >5	240
Ribavirin	>1640	1000 >1.6	1000 >1.6	1000 >1.6	1000 >1.6	>1650	1650	200 >8	1000 >1.6	200 >8	200 >8
ACG	355	0.75 430	0.75 430	0.75 430	1.7 210	0.75 430	1.7 210	>355	355	42.6 8.3	8.5 42
DHPG	>400	0.15 2670	0.15 2670	0.0045 88900	0.074 5200	0.074 5200	0.074 5200	>400	>400	0.38 1050	0.38 1050

^a Required to cause a microscopically detectable alteration of normal cell morphology.^b Required to reduce virus-induced cytopathogenicity by 50%.^c Selectivity index

Table 2. Antiviral activity and cytotoxicity of TEDU phosphonate (II, R=COOEt) in E6BM cell cultures.

Compound	minimum cytotoxic concentration, mM ^a	Minimum inhibitory concentration ^b , mM									
		HSV-1 (KOS)	HSV-1 (F)	HSV-1 (McIntyre)	HSV-2 (G)	HSV-2 (196)	HSV-2 (Lysen)	Vaccinia virus	Vectator retrovirus	HSV-1 TK ^c (B2006)	HSV-1 TK ^c (VMW 1077)
II, R=COOEt	>950	0.036 >26400	0.012 >73200	0.036 >26400	0.17 >5590	0.03 >31700	0.15 >6350	0.30 >3170		7.53 >130	1.5 >635
BVDU	>240	0.077 >3120	0.046 >5220	0.046 >5220	>240	>240	>240	5.76 >42		240	240
Ribavirin	>1640	65.8 >25	65.8 >25	39.5 >40	200 >8	200 >8	200 >8	65.8 >25		65.8 >25	200 >6
ACG	355	0.33 1075	0.115 3085	0.57 625	0.33 1075	0.57 625		>355		14.2 25	8.53 42
DHPG	400	0.015 26700	0.0078 5120	0.005 80000	0.078 5130	0.078 5130	0.125 3200	>400		0.63 635	0.125 3200


^a Required to cause a microscopically detectable alteration of normal cell morphology.^b Required to reduce virus-induced cytopathogenicity by 50%.^c Selectivity index

REFERENCES

1. Walker R.T., Whale R.F., Dyson M.R., Coe P.L., Alderton W., Collins P., Ertl P., Lowe D., Rahim G., Snowden W., Litter E. Antiviral properties of 4'-S-WDTU, *Nucleic Acids Res.*, 31 (Symp...Ser.) 9-10.
2. Rahim S.D., Trivedi N., Bogdanovic-Batchelor M.V., Hardy G.W., Mils G., Serway J.W-T., Littler E., Coe P.L., Basnak I., Whale R.F., Walker R.T., Synthesis and antiherpesvirus activity of 2'-deoxy-4'-thiopyrimidine nucleosides, *J.Med.Chem.*, 1996, 39, 789-795.
3. Alexandrova L.A., Semizarov D.G., Krayevsky A.A., Walker R.T., 4'-Thio-5-ethyl-2'-deoxyuridine 5'-triphosphate (TEDUTP): synthesis and substrate properties in DNA-synthesizing systems, *Antiviral Chem.Chemother.* 1996, 7, 237-242.
4. Crumpacker C.S., Schnipper L.E., Zaia J.A., Levene M., *Antimicrob. Agents Chemother.* 1979, 15, 642-645.

We claim:


1. 4'-Thio-5-ethyl-2'-deoxyuridine 5'-phosphonate of the formula:



(II)

wherein R=H, CONH₂, AlkylOOC, Alkyl, Haloidalkyl, dihaloidalkyls, trihaloidalkyl, HOCH₂, AcylOCH₂

2. 4'-Thio-5-ethyl-2'-deoxyuridine 5'-phosphonate of the formula (II) of claim 1 for use in selectively inhibiting HSV-1 HSV-2, TK HSV-1, HCMV and VV;
3. 4'-Thio-5-ethyl-2'-deoxyuridine 5'-phosphonate of the formula (II) of claim 1 for use in the prophylactic treatment of HSV-1, HSV-2, TK HSV-1, HCMV and VV.
4. 4'-Thio-5-ethyl-2'-deoxyuridine P-substituted 5'-phosphonates of the formula:



(III)

wherein R=H, CONH₂, AlkylOOC, Alkyl, Haloidalkyl, dihaloidalkyls, trihaloidalkyl, HOCH₂, AcylOCH₂ and R'=O-alkyl, O-aminoalkyls, O-hydroxyalkyls, O-glycosyl

5. 4'-Thio-5-ethyl-2'-deoxyuridine P-substituted 5'-phosphonates of the formula (III) for use in selectively inhibiting HSV-1, HSV-2, TKHSV-1, HCMV and VV.

6. 4'-Thio-5-ethyl-2'-deoxyuridine P-substituted 5'-phosphonates of the formula (III) for use in the prophylactic treatment of HSV-1, HSV-2, TKHSV-1, HCMV and VV.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H19/10 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ALEXandrova L A ET AL: "4'-thio-5-ethyl-2'-deoxyuridine 5'-triphosphate (TEDUTP): synthesis and substrate properties in DNA-synthesizing systems" ANTIVIRAL CHEM. CHEMOTHER. (ACCHEH,09563202);1996; VOL.7 (5); PP.237-242, XP002116568 Russian Acad. Sci.;Engelhardt Inst. Molecular Biol.; Moscow; 117984; Russia (RU) cited in the application the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 November 1999

Date of mailing of the international search report

17/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WALKER R T ET AL: "Antiviral properties of 4'-S-ETDU" NUCLEIC ACIDS SYMP. SER: (NACSD8,02613166);1994; VOL.31 (21ST SYMPOSIUM ON NUCLEIC ACIDS CHEMISTRY, 1994); PP.9-10, XP002116569 Univ. Birmingham;Sch. Chem.; Birmingham; B15 2TT; UK (GB) cited in the application the whole document	1-6
Y	EP 0 409 575 A (THE UNIVERSITY OF BIRMINGHAM) 23 January 1991 (1991-01-23) the whole document	1-6
Y	EP 0 421 777 A (THE UNIVERSITY OF BIRMINGHAM) 10 April 1991 (1991-04-10) the whole document	1-6

Information on patent family members

International Application no

PCT/CA 99/00465

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 409575	A	23-01-1991	AT 161267 T	15-01-1998
			AU 669040 B	23-05-1996
			AU 5635294 A	19-05-1994
			AU 668270 B	26-04-1996
			AU 5635394 A	05-05-1994
			AU 648746 B	05-05-1994
			AU 5963490 A	22-02-1991
			CA 2065279 A	18-01-1991
			DD 296688 A	12-12-1991
			WO 9101326 A	07-02-1991
			IL 95103 A	31-03-1996
			JP 2502813 B	29-05-1996
			JP 4506661 T	19-11-1992
			LT 278 A,B	27-12-1994
			LV 10104 A,B	10-05-1994
			MX 9203668 A	01-09-1992
			NO 178930 B	25-03-1996
			NZ 234534 A	22-12-1994
			NZ 244365 A	22-12-1994
			NZ 247461 A	22-12-1994
			PL 167317 B	31-08-1995
			PT 94731 A,B	20-03-1991
			US 5356882 A	18-10-1994
			AT 134644 T	15-03-1996
			AU 656122 B	27-01-1995
			AU 6441390 A	28-04-1991
			CA 2067094 A	05-04-1991
			DE 69025529 D	04-04-1996
			DE 69025529 T	17-10-1996
			EP 0421777 A	10-04-1991
			ES 2086376 T	01-07-1996
			WO 9104982 A	18-04-1991
			IE 74701 B	30-07-1997
			NZ 235537 A	23-12-1992
			PT 95510 A,B	14-08-1991
EP 421777	A	10-04-1991	AT 134644 T	15-03-1996
			AU 656122 B	27-01-1995
			AU 6441390 A	28-04-1991
			CA 2067094 A	05-04-1991
			DE 69025529 D	04-04-1996
			DE 69025529 T	17-10-1996
			ES 2086376 T	01-07-1996
			WO 9104982 A	18-04-1991
			IE 74701 B	30-07-1997
			NZ 235537 A	23-12-1992
			PT 95510 A,B	14-08-1991
			AT 161267 T	15-01-1998
			AU 669040 B	23-05-1996
			AU 5635294 A	19-05-1994
			AU 668270 B	26-04-1996
			AU 5635394 A	05-05-1994
			AU 648746 B	05-05-1994
			AU 5963490 A	22-02-1991
			CA 2065279 A	18-01-1991
			EP 0409575 A	23-01-1991
			WO 9101326 A	07-02-1991
			IL 95103 A	31-03-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00465

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 421777 A		JP 2502813 B	29-05-1996
		JP 4506661 T	19-11-1992
		LV 10104 A,B	10-05-1994
		MX 9203668 A	01-09-1992
		NO 178930 B	25-03-1996
		NZ 234534 A	22-12-1994
		NZ 244365 A	22-12-1994
		NZ 247461 A	22-12-1994
		PL 167317 B	31-08-1995
		PT 94731 A,B	20-03-1991
		US 5356882 A	18-10-1994

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.